Transformative Paths: Preclinical Drug Formulation and Delivery Approaches in Development.

Area of Science:

• Pharmacology
• Drug Development
• Regulatory Science

Background:

• Preclinical drug development is a critical phase for evaluating drug safety and efficacy before human trials.
• Navigating regulatory requirements and Investigational New Drug (IND) submissions presents significant challenges.
• Optimizing drug formulation is essential for enhancing bioavailability and therapeutic outcomes.

Purpose of the Study:

• To provide a comprehensive overview of preclinical drug development stages.
• To detail regulatory aspects, including Investigational New Drug (IND) submissions.
• To explore innovative preformulation strategies for improved drug delivery.

Main Methods:

• Review of existing literature on preclinical studies, pharmacokinetics, pharmacodynamics, and safety assessments.
• Analysis of regulatory guidelines from global health authorities.
• Examination of novel formulation techniques such as nanotechnology and solid dispersions.

Main Results:

• Preclinical studies in animal models are vital for safety and efficacy evaluation.
• Adherence to global regulatory standards is mandatory for Investigational New Drug (IND) approval.
• Advanced formulation strategies significantly improve drug solubility, stability, and bioavailability.

Conclusions:

• Successful preclinical development requires rigorous scientific evaluation and regulatory compliance.
• Innovative formulation approaches are key to overcoming drug delivery challenges.
• This review offers guidance for researchers and professionals in preclinical drug development and regulatory affairs.